Here is some other vaccine news of note for the week.
> Even a flu vaccine 20% effective would avert 21 million infections and save 61,000 lives, as long as about 40% of Americans got their shots, a new study led by Yale University researchers found. HealthDay News article
> CureVac’s founder and CEO Ingmar Hoerr, Ph.D., plans to transition to chairman, handing the reins over to current CBO and U.S. subsidiary CEO Daniel Menichella. Release
> Bavarian Nordic announced the FDA has granted orphan drug designation to its cancer vaccine BN-Brachyury for the treatment of chordoma. Release
> British firm Scancell raised £8.7 million in a public offering to help advance the development of its cancer vaccines. Labiotech article
> The Scripps Research Institute landed a $12 million grant from the Bill & Melinda Gates Foundation to study vaccines that can neutralize many strains of malaria and influenza. Release
> Emergent BioSolutions reported $117.8 million in revenues from the first quarter, hurt by delays in the delivery of BioThrax and ACAM2000. Release